Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2005Clinical Cancer ResearchOpen Access

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

View Full Paper
Ask AI
Bookmark
Share

Authors

UBUdai BanerjiRoyal Marsden NHS Foundation TrustMWMichael I. WaltonInstitute of Cancer ResearchFRFlorence I. RaynaudInstitute of Cancer Research

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Banerji et al. (2005) studied this question.

synapsesocial.com/papers/6a6fa28526a7f98052dc436bhttps://doi.org/10.1158/1078-0432.ccr-05-0518
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Stable Association of hsp90 and p23, but Not hsp70, with Active Human Telomerase2001 · 248 citations
  2. 2The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors2003 · 205 citations
  3. 3Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer2005 · 336 citations